Vir Biotechnology downgraded by BofA Securities with a new price target
$VIR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously